Strongly bactericidal all-oral β-lactam combinations for the treatment of *Mycobacterium abscessus* lung disease

Dereje A. Negatu,[a,b] Matthew D. Zimmerman,[a] Véronique Dartois,[a, c] Thomas Dick[a, c, d]#

[a] Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA

[b] Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia

[c] Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA

[d] Department of Microbiology and Immunology, Georgetown University, Washington, DC, USA

Running Title: Combination of oral β-lactams against *M. abscessus*

Keywords: Non-tuberculous mycobacteria, NTM, synergy, sulopenem, tebipenem, cefuroxime, amoxicillin, avibactam

#Address correspondence to Thomas Dick: thomas.dick.cdi@gmail.com

ABSTRACT

Bioactive forms of oral β-lactams were screened in vitro against *Mycobacterium abscessus* with and without the bioactive form of the oral β-lactamase inhibitor avibactam-ARX1796. Sulopenem was equally active without avibactam, while tebipenem, cefuroxime and amoxicillin required avibactam for optimal activity. Systematic pairwise combination of the four β-lactams revealed strong bactericidal synergy for each of sulopenem, tebipenem and cefuroxime combined with amoxicillin in the presence of avibactam. These all-oral β-lactam combinations warrant clinical evaluation.

MAIN TEXT

M. abscessus lung disease is treated with an oral macrolide (clarithromycin (CLR) or azithromycin) in combination with several, largely underperforming antibiotics including parenteral amikacin, one of the two parenteral β-lactams imipenem (IPM) or cefoxitin (FOX), and tigecycline (1). Patients are often treated for years, until sputum cultures remain negative for 12 months, if culture conversion is achieved. Chemotherapies, complicated by the need to use injectable drugs, are not only long but often toxic (1, 2). Treatment is further tangled by widespread inducible resistance to the oral macrolide component due to the presence of the ribosome methylase gene *erm41* (3-5). In short, there is no reliable cure for *M. abscessus* lung disease. Novel, well tolerated, bactericidal, and importantly, oral treatment options are sorely needed (6, 7).

β-lactams are bactericidal and display overall excellent tolerability profiles (8). However, IPM and FOX, the standard of care carbapenem and cephalosporin, are administered intravenously, limiting their clinical utility given the very long treatment duration required to

control or cure *M. abscessus* lung disease. They also show modest in vitro activity (9, 10), leading to poor pharmacokinetic-pharmacodynamic target attainment compared to those achieved against other bacterial infections.

Different classes of β-lactams, and different members within a class, differentially inhibit the numerous *M. abscessus* transpeptidases and other enzymes involved in peptidoglycan synthesis (11-16). Thus, multiple recent reports have demonstrated the potential of combining two β-lactams to achieve additive and synergistic effects in vitro (17-21) as well as in vivo (22).

A number of oral β-lactams are in clinical development or in clinical use for other bacterial infections (23, 24). Furthermore, an oral form (ARX1796) of the β-lactamase inhibitor avibactam (AVI), inhibiting the major β-lactamase MAB_2875 of *M. abscessus* (9, 25), recently entered clinical development (26) (ClinicalTrials.gov Identifier: NCT03931876).

Here, our goal was to identify oral β-lactam pairs that exert synergistic bactericidal activity (with or without oral AVI) and can be repurposed to treat *M. abscessus* lung disease. First, a collection of the bioactive forms of 22 oral β-lactams, including penems, carbapenems, cephalosporins and penicillins, was screened at a single concentration of 12.5 μM with and without the bioactive form of AVI at a fixed concentration of 4 μg/ml (14 μM) to identify antibiotics with attractive anti-*M. abscessus* growth inhibitory activity (27). Growth inhibition against the type strain *M. abscessus* susbsp. *abscessus* ATCC19977 was measured in 7H9 broth using OD_{600} as readout (28). Applying > 80 % growth inhibition as cut-off, we identified one penem (sulopenem, SUP), one carbapenem (tebipenem, TBP), one cephalosporin, (cefuroxime, CXM) and two penicillins (ampicillin (AMP) and amoxicillin

(AMX)) as active agents. At 12.5 µM, SUP and CXM were equally active with and without AVI. TBP, AMP and AMX required AVI for activity (Figure 1, Figure S1).

To confirm the results from the single point screen, we determined the minimum inhibitory concentration (MIC) of SUP, TBP, CXM, and AMX (the early generation penicillin AMP was not followed up) with or without AVI (4 µg/mL). MIC was defined as 90% growth inhibition and derived from dose response curves (28) (Table 1, Figure S2). The MIC of SUP was 2.5 µM and AVI-independent. TBP had an MIC of 4 µM in the presence of AVI. CXM showed a weak AVI dependency, with MICs of 5 µM and 10 µM with and without AVI, respectively. AMX exhibited a unique activity profile with a modest MIC of 25 µM in the presence of AVI but a substantially lower MIC_{50} (concentration inhibiting 50% of growth) of 3 µM, similar to the MIC_{50} of SUP, TBP and CXM (Figure S2). The two injectable comparators IPM and FOX (which are both AVI independent (9)) showed MICs of 20 and 30 µM as reported (9). (Table 1, Figure S2).

To confirm the growth inhibitory activity of SUP, TBP+AVI, CXM+AVI and AMX+AVI in an orthogonal assay, we determined their MIC against *M. abscessus* ATTC19977 using the agar dilution method (29) and found agar MICs in the range of broth MICs (Figure S3), with the exception of AMX which interestingly had a lower agar than liquid MIC (6 µM versus 25 µM).

To determine whether the attractive activity of SUP, TBP+AVI, CXM+AVI and AMX+AVI against the type strain *M. abscessus* susbsp. *abscessus* ATCC19977 was retained against the broader *M. abscessus* complex (30), broth MICs were measured against the reference strains of the two other subspecies *M. abscessus* subsp. *bolletii* CCUG50184T and *M. abscessus* subsp. *massiliense* CCUG48898T, as well as a panel of clinical isolates, including *erm41*

macrolide resistant strains (Table 1, Figure S2). Potency of the active β-lactams was largely comparable across the three subspecies of the *M. abscessus* complex. Again, CXM activity was 2 to 3-fold enhanced in the presence of AVI and AMX+AVI displayed modest MIC_{90} (Table 1), but substantially lower (3 – 4 μM) MIC_{50} (Figure S2).

Next, we measured the bactericidal activity in dose response time-kill experiments (28). *M. abscessus* ATCC19977 cultures were grown in 7H9 and treated with MIC multiples of the β-lactams for 5 days (in the presence of 4 μg/mL AVI when required), and CFU were measured by plating samples on 7H10 agar. All four β-lactams achieved pronounced reductions in viable counts, up to 4-log CFU reduction after 3 days of incubation with 8-fold MIC (Figure 2A). Interestingly, regrowth was observed in most cultures between day 3 and 5 for the oral β-lactams, and even earlier for the injectables, which we hypothesized was associated with the limited aqueous stability of β-lactams (31, 32). To test the potential decay hypothesis, drug concentrations were followed in 7H9 medium over 5 days using high-pressure liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) (33). The lactam ring-containing drugs (i.e., all study drugs but not AVI) were unstable to various extents, mostly in line with the extent and timing of regrowth of the cultures (Figure 2B). Half-lives (t ½) of the β-lactams in 7H9 ranged from ~0.5 days for the markedly unstable IMP used as comparator (32) to ~5 days for the most stable SUP (Figure 2B). Since β-lactams also undergo spontaneous and enzymatic hydrolysis in plasma (34), we measured stability of the four oral β-lactams and AVI in mouse plasma to determine which pair would be most suitable for in vivo efficacy in murine models of *M. abscessus* infection. We found that TBP, AMX and AVI have a plasma t ½ ≥ 24h (Figure 2C), indicating that the TBP/AMX+AVI

combinations could be prioritized as a case study to determine how these in vitro bactericidal synergies translate in vivo.

Taken together, these results confirm and extend prior studies showing attractive growth inhibitory and bactericidal anti-*M. abscessus* activity of SUP (35), TBP+AVI (27), CXM+AVI (9) and AMX+AVI (9), suggesting them as repurposing candidates.

To determine potential growth inhibition synergies of the four β-lactams, systematic pairwise checkerboard analyses were carried out with *M. abscessus* ATCC19977 (36). AVI was included at 4 μg/mL in all assays as at least one partner of each dual combination requires the β-lactamase inhibitor (Table 2). Interestingly, the three AMX-containing pairs were synergistic, while the other three were additive (Table 2). Synergistic activity of the AMX-containing pairs was confirmed in checkerboard assays against the broader *M. abscessus* complex and the clinical isolate collection. TBP and CXM combined with AMX retained strong synergistic activity against all tested strains and isolates, while SUP+AMX was additive against some of the isolates (Table 3).

To determine whether the three synergistic β-lactam pairs also exerted potentiation of bactericidal activity, time-kill experiments were carried out with *M. abscessus* ATCC19977 in 7H9 and the effect of treatment on viability was measured by plating on 7H9 agar (28). To uncover potential bactericidal synergy, we combined SUP, TBP or CXM at their MIC, concentrations that achieve little bactericidal effect (Figure 2A), with AMX at 10 μM (at which the drug inhibits 80 % growth, Figure S2)) and 4 μg/mL AVI. Impressively, each of the three combinations achieved more than 4-log reduction in viable counts after 3 days of treatment (Figure 3). In comparison, 8x MIC of each individual β-lactam was required to achieve a similar degree of killing (Figure 2). Further reducing AMX concentration to 5 or

129 2.5 μM still achieved a 4-log reduction after 5 days of treatment, reenforcing the notion that
130 AMX strongly potentiates the bactericidal activity of SUP, TBP and CXM. In addition, the
131 combinations not only killed effectively at lower concentrations than individual β lactams,
132 they also prevented the re-growth observed in cultures treated with single drugs (Figure 2A).

133 In conclusion, four oral β-lactams SUP, TBP, CXM and AMX were identified as bactericidal
134 against *M. abscessus* at clinically achievable concentrations. TBP, CXM and AMX required
135 the β-lactamase inhibitor AVI for optimal activity whereas SUP's activity was AVI
136 independent. Pairwise combinations revealed three novel triple combinations (SUP or TBP or
137 CXM with AMX plus AVI) showing both bacteriostatic and bactericidal synergy.
138 Interestingly, all three β-lactam pairs contained AMX, which preferentially targets *M.*
139 *abscessus* D,D-carboxypeptidase (14), whereas the carbapenem TBP was shown to inhibit
140 L,D-transpeptidases Ldt_{Mab1} and Ldt_{Mab2} (13) and D,D-transpeptidases PonA1, PonA2, and
141 PbpA (11). The specific targets of SUP and CXM have not been identified. However, similar
142 to TBP, other penems and cephalosporins were also shown to preferentially target L,D- and
143 D,D-transpeptidases (11-13). The differential inhibition of D,D-carboxypeptidase by AMX
144 and of L,D- and D,D-transpeptidases by TBP and possibly SUP and CXM may provide the
145 mechanistic basis for the observed synergistic effects of the AMX-containing β-lactam
146 couples, since they would inhibit different enzymes of the same cellular process, i.e.
147 peptidoglycan synthesis. Oral forms of SUP and TBP as well as AVI are currently in clinical
148 development for other diseases and oral CXM and AMX are approved drugs (Table S1).
149 Thus, the compounds and combinations identified in this study present drug candidates that
150 can enter clinical development for *M. abscessus* lung disease.

151 **ACKNOWLEDGMENTS**

We are grateful to Wei Chang Huang (Taichung Veterans General Hospital, Taichung, Taiwan) for providing *M. abscessus* Bamboo, to Jeanette W.P. Teo (Department of Laboratory Medicine, National University Hospital, Singapore) for providing the collection of *M. abscessus* clinical M isolates, and to Sung Jae Shin (Department of Microbiology, Yonsei University College of Medicine, Seoul, South Korea) and Won-Jung Koh (Division of Pulmonary and Critical Care Medicine, Samsung Medical Center, Seoul, South Korea) for providing *M. abscessus* K21. We thank Rubén González del Río and Mónica Cacho-Izquierdo (Global Health Pharma Unit, GlaxoSmithKline, Tres Cantos, Madrid, Spain) for valuable discussion. Research reported in this work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI132374. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

AUTHOR CONTRIBUTIONS

Investigation: D.A.N., M.D.Z.; Writing – Original Draft: D.A.N., T.D.; Writing – Review & Editing: all authors; Funding Acquisition: T.D.; Supervision: V.D., T.D.

CONFLICT OF INTEREST STATEMENT

The authors declare no commercial or financial relationships that could be construed as a potential conflict of interest.

173

174

175

176 **REFERENCES**

177 1. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Jr., Andrejak C, Böttger EC,
178 Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK,
179 Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. 2020.
180 Treatment of nontuberculous mycobacterial pulmonary disease: an official
181 ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 56. doi:
182 10.1183/13993003.00535-2020.

183 2. Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley
184 CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE,
185 Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M,
186 Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM. 2019. Advancing Translational
187 Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for
188 Research. Am J Respir Crit Care Med 199:947-951. doi: 10.1164/rccm.201807-1273PP.

189 3. Brown-Elliott BA, Vasireddy S, Vasireddy R, Iakhiaeva E, Howard ST, Nash K, Parodi
190 N, Strong A, Gee M, Smith T, Wallace RJ, Jr. 2015. Utility of sequencing the erm(41)
191 gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate
192 clarithromycin MICs. J Clin Microbiol 53:1211-5. doi: 10.1128/JCM.02950-14

193 4. Griffith DE, Daley CL. 2022. Treatment of Mycobacterium abscessus Pulmonary
194 Disease. Chest 161:64-75. doi: 10.1016/j.chest.2021.07.035.

195 5. Luthra S, Rominski A, Sander P. 2018. The Role of Antibiotic-Target-Modifying and
196 Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance. Front
197 Microbiol 9:2179. doi: 10.3389/fmicb.2018.02179.
198 6. Wu ML, Aziz DB, Dartois V, Dick T. 2018. NTM drug discovery: status, gaps and the
199 way forward. Drug Discov Today 23:1502-1519. doi: 10.1016/j.drudis.2018.04.001.
200 7. Egorova A, Jackson M, Gavrilyuk V, Makarov V. 2021. Pipeline of anti-Mycobacterium
201 abscessus small molecules: Repurposable drugs and promising novel chemical entities.
202 Med Res Rev 41:2350-2387. doi: 10.1002/med.21798.
203 8. Story-Roller E, Maggioncalda EC, Cohen KA, Lamichhane G. 2018. Mycobacterium
204 abscessus and β-Lactams: Emerging Insights and Potential Opportunities. Front
205 Microbiol 9:2273. doi: 10.3389/fmicb.2018.02273.
206 9. Dubée V, Bernut A, Cortes M, Lesne T, Dorchene D, Lefebvre AL, Hugonnet JE,
207 Gutmann L, Mainardi JL, Herrmann JL, Gaillard JL, Kremer L, Arthur M. 2015. β-
208 Lactamase inhibition by avibactam in Mycobacterium abscessus. J Antimicrob
209 Chemother 70:1051-8. doi: 10.1093/jac/dku510.
210 10. Lavollay M, Dubée V, Heym B, Herrmann JL, Gaillard JL, Gutmann L, Arthur M,
211 Mainardi JL. 2014. In vitro activity of cefoxitin and imipenem against Mycobacterium
212 abscessus complex. Clin Microbiol Infect 20:O297-300. doi: 10.1111/1469-0691.12405.
213 11. Sayed ARM, Shah NR, Basso KB, Kamat M, Jiao Y, Moya B, Sutaria DS, Lang Y, Tao
214 X, Liu W, Shin E, Zhou J, Werkman C, Louie A, Drusano GL, Bulitta JB. 2020. First
215 Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase
216 Inhibitors in Mycobacterium abscessus. Antimicrob Agents Chemother 65. doi:
217 10.1128/AAC.01956-20.

218 12. Dousa KM, Kurz SG, Taracila MA, Bonfield T, Bethel CR, Barnes MD, Selvaraju S,
219 Abdelhamed AM, Kreiswirth BN, Boom WH, Kasperbauer SH, Daley CL, Bonomo RA.
220 2020. Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium
221 abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. Antimicrob
222 Agents Chemother 64. doi: 10.1128/AAC.00098-20.
223 13. Kumar P, Chauhan V, Silva JRA, Lameira J, d'Andrea FB, Li SG, Ginell SL, Freundlich
224 JS, Alves CN, Bailey S, Cohen KA, Lamichhane G. 2017. Mycobacterium abscessus l,d-
225 Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but
226 Not Penicillins. Antimicrob Agents Chemother 61. doi: 10.1128/AAC.00866-17.
227 14. Dousa KM, Nguyen DC, Kurz SG, Taracila MA, Bethel CR, Schinabeck W, Kreiswirth
228 BN, Brown ST, Boom WH, Hotchkiss RS, Remy KE, Jacono FJ, Daley CL, Holland SM,
229 Miller AA, Bonomo RA. 2022. Inhibiting Mycobacterium abscessus Cell Wall Synthesis:
230 Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action.
231 mBio 13:e0352921. doi: 10.1128/mbio.03529-21.
232 15. Rifat D, Chen L, Kreiswirth BN, Nuermberger EL. 2021. Genome-Wide Essentiality
233 Analysis of Mycobacterium abscessus by Saturated Transposon Mutagenesis and Deep
234 Sequencing. mBio 12:e0104921. doi: 10.1128/mBio.01049-21.
235 16. Kurepina N, Chen L, Composto K, Rifat D, Nuermberger EL, Kreiswirth BN. 2022.
236 CRISPR Inhibition of Essential Peptidoglycan Biosynthesis Genes in Mycobacterium
237 abscessus and Its Impact on β-Lactam Susceptibility. Antimicrob Agents Chemother
238 66:e0009322. doi: 10.1128/aac.00093-22.

239 17. Story-Roller E, Maggioncalda EC, Lamichhane G. 2019. Select β-Lactam Combinations
240 Exhibit Synergy against Mycobacterium abscessus In Vitro. Antimicrobial agents and
241 chemotherapy 63:e02613-18. doi: 10.1128/AAC.02613-18.
242 18. Story-Roller E, Galanis C, Lamichhane G. 2021. β-Lactam Combinations That Exhibit
243 Synergy against Mycobacteroides abscessus Clinical Isolates. Antimicrob Agents
244 Chemother 65. doi: 10.1128/AAC.02545-20.
245 19. Pandey R, Chen L, Manca C, Jenkins S, Glaser L, Vinnard C, Stone G, Lee J, Mathema
246 B, Nuermberger EL, Bonomo RA, Kreiswirth BN. 2019. Dual β-Lactam Combinations
247 Highly Active against Mycobacterium abscessus Complex In Vitro. mBio 10. doi:
248 10.1128/mBio.02895-18.
249 20. Nguyen DC, Dousa KM, Kurz SG, Brown ST, Drusano G, Holland SM, Kreiswirth BN,
250 Boom WH, Daley CL, Bonomo RA. 2021. "One-Two Punch": Synergistic ß-Lactam
251 Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of
252 Peptidoglycan Synthesis Enzymes. Clin Infect Dis 73:1532-1536. doi:
253 10.1093/cid/ciab535.
254 21. Rimal B, Batchelder HR, Story-Roller E, Panthi CM, Tabor C, Nuermberger EL,
255 Townsend CA, Lamichhane G. 2022. T405, a New Penem, Exhibits In Vivo Efficacy
256 against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren. Antimicrob
257 Agents Chemother doi:10.1128/aac.00536-22:e0053622.
258 22. Story-Roller E, Maggioncalda EC, Lamichhane G. 2019. Synergistic Efficacy of β-
259 Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice.
260 Antimicrob Agents Chemother 63. doi: 10.1128/AAC.00614-19.

261 23. Mogle BT, Beccari MV, Steele JM, Fazili T, Kufel WD. 2019. Clinical considerations for
262 oral beta-lactams as step-down therapy for Enterobacteriaceae bloodstream infections.
263 Expert Opin Pharmacother 20:903-907. doi: 10.1080/14656566.2019.1594774.
264 24. Veeraraghavan B, Bakthavatchalam YD, Sahni RD. 2021. Oral Antibiotics in Clinical
265 Development for Community-Acquired Urinary Tract Infections. Infect Dis Ther
266 10:1815-1835.
267 25. Soroka D, Dubée V, Soulier-Escrihuela O, Cuinet G, Hugonnet JE, Gutmann L, Mainardi
268 JL, Arthur M. 2014. Characterization of broad-spectrum Mycobacterium abscessus class
269 A β-lactamase. J Antimicrob Chemother 69:691-6. doi: 10.1007/s40121-021-00509-4.
270 26. Gordon EM, Duncton MAJ, Gallop MA. 2018. Orally Absorbed Derivatives of the β-
271 Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs.
272 Journal of Medicinal Chemistry 61:10340-10344. doi: 10.1021/acs.jmedchem.8b01389.
273 27. Kaushik A, Gupta C, Fisher S, Story-Roller E, Galanis C, Parrish N, Lamichhane G.
274 2017. Combinations of avibactam and carbapenems exhibit enhanced potencies against
275 drug-resistant Mycobacterium abscessus. Future Microbiol 12:473-480. doi:
276 10.2217/fmb-2016-0234.
277 28. Negatu DA, Beuchel A, Madani A, Alvarez N, Chen C, Aragaw WW, Zimmerman MD,
278 Laleu B, Gengenbacher M, Dartois V, Imming P, Dick T. 2021. Piperidine-4-
279 Carboxamides Target DNA Gyrase in Mycobacterium abscessus. Antimicrob Agents
280 Chemother 65:e0067621. doi: 10.1128/AAC.00676-21.
281 29. Anonymous. 2000. EUCAST Definitive Document E.DEF 3.1, June 2000: Determination
282 of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution.
283 Clin Microbiol Infect 6:509-15. doi: 10.1046/j.1469-0691.2000.00142.x.

284 30. Johansen MD, Herrmann JL, Kremer L. 2020. Non-tuberculous mycobacteria and the rise
285 of Mycobacterium abscessus. Nat Rev Microbiol 18:392-407. doi: 10.1038/s41579-020-
286 0331-1.
287 31. Brouwers R, Vass H, Dawson A, Squires T, Tavaddod S, Allen RJ. 2020. Stability of β-
288 lactam antibiotics in bacterial growth media. PLoS One 15:e0236198. doi:
289 10.1371/journal.pone.0236198.
290 32. Rominski A, Schulthess B, Müller DM, Keller PM, Sander P. 2017. Effect of β-lactamase
291 production and β-lactam instability on MIC testing results for Mycobacterium abscessus.
292 J Antimicrob Chemother 72:3070-3078. doi: 10.1093/jac/dkx284.
293 33. Gold B, Zhang J, Quezada LL, Roberts J, Ling Y, Wood M, Shinwari W, Goullieux L,
294 Roubert C, Fraisse L, Bacqué E, Lagrange S, Filoche-Rommé B, Vieth M, Hipskind PA,
295 Jungheim LN, Aubé J, Scarry SM, McDonald SL, Li K, Perkowski A, Nguyen Q, Dartois
296 V, Zimmerman M, Olsen DB, Young K, Bonnett S, Joerss D, Parish T, Boshoff HI,
297 Arora K, Barry CE, 3rd, Guijarro L, Anca S, Rullas J, Rodríguez-Salguero B, Martínez-
298 Martínez MS, Porras-De Francisco E, Cacho M, Barros-Aguirre D, Smith P, Berthel SJ,
299 Nathan C, Bates RH. 2022. Identification of β-Lactams Active against Mycobacterium
300 tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.
301 ACS Infect Dis 8:557-573. doi: 10.1021/acsinfecdis.1c00570.
302 34. Smith PW, Zuccotto F, Bates RH, Martinez-Martinez MS, Read KD, Peet C, Epemolu O.
303 2018. Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover
304 Long-Acting Oral Drugs in the Future. ACS Infectious Diseases 4:1439-1447. doi:
305 10.1021/acsinfecdis.8b00160.

306 35. Dousa KM, Nguyen DC, Kurz SG, Taracila MA, Bethel C, Bonomo RA. 2020. 1572.
307 Combination Cefuroxime and Sulopenem is active in vitro against Mycobacterium
308 abscessus. Open Forum Infectious Diseases 7:S785-S785. doi:
309 10.1093/ofid/ofaa439.1752.
310 36. Aziz DB, Teo JWP, Dartois V, Dick T. 2018. Teicoplanin – Tigecycline Combination
311 Shows Synergy Against Mycobacterium abscessus. Frontiers in Microbiology 9. doi:
312 10.3389/fmicb.2018.00932.
313 37. Yee M, Klinzing D, Wei JR, Gengenbacher M, Rubin EJ, Dick T. 2017. Draft Genome
314 Sequence of Mycobacterium abscessus Bamboo. Genome Announc 5. doi:
315 10.1128/genomeA.00388-17.
316 38. Dick T, Shin SJ, Koh WJ, Dartois V, Gengenbacher M. 2020. Rifabutin Is Active against
317 Mycobacterium abscessus in Mice. Antimicrob Agents Chemother 64. doi:
318 10.1128/AAC.01943-19.
319 39. Aziz DB, Low JL, Wu ML, Gengenbacher M, Teo JWP, Dartois V, Dick T. 2017.
320 Rifabutin Is Active against Mycobacterium abscessus Complex. Antimicrob Agents
321 Chemother 61. doi: 10.1128/AAC.01943-19.
322 40. Anonymous. 2000. EUCAST Definitive Document E.Def 1.2, May 2000: Terminology
323 relating to methods for the determination of susceptibility of bacteria to antimicrobial
324 agents. Clin Microbiol Infect 6:503-8. doi: 10.1046/j.1469-0691.2000.00149.x.

325

326 **TABLES**

327 **Table 1.** Activity of SUP, TBP, CXM and AMX without and with 4 µg/mL AVI against *M. abscessus* complex strains.[a]

***M. abscessus* strain**	***erm41*[d] sequevar**	**CLR susceptibility**	**SUP**		**TBP**		**CXM**		**AMX**		**IPM[b]**	**FOX[b]**	**CLR[c]**
			MIC	MIC+	MIC	MIC+	MIC	MIC+	MIC	MIC+	MIC	MIC	MIC
Reference strains													
subsp. *abscessus* ATCC19977	T28	Resistant	2.5	2.0	25.0	4.0	10.0	5.0	>100	25.0[a]	20.0	30.0	1.6
subsp. *bolletii* CCUG50184T	T28	Resistant	3.5	2.0	30.0	5.0	20.0	10.0	>100	40.0	30.0	30.0	5.0
subsp. *massiliense* CCUG48898T	Deletion	Sensitive	7.0	5.0	40.0	7.0	30.0	10.0	>100	100.0	40.0	45.0	0.4
Clinical isolates[e]													
subsp. *abscessus* Bamboo	C28	Sensitive	3.0	2.5	25.0	4.0	10.0	8.0	>100	40.0	20.0	35.0	0.4
subsp. *abscessus* K21	C28	Sensitive	6.3	5.0	40.0	4.0	30.0	20.0	>100	100.0	25.0	40.0	0.5
subsp. *abscessus* M9	T28	Resistant	3.0	2.5	35.0	3.5	10.0	5.0	>100	40.0	15.0	35.0	2.5
subsp. *abscessus* M199	T28	Resistant	3.0	2.5	25.0	3.0	12.5	8.0	>100	75.0	20.0	35.0	6.0
subsp. *abscessus* M337	T28	Resistant	2.0	2.2	30.0	3.0	10.0	8.0	>100	60.0	15.0	30.0	3.0
subsp. *abscessus* M404	C28	Sensitive	3.5	2.5	30.0	3.5	20.0	7.0	>100	40.0	20.0	35.0	0.4
subsp. *abscessus* M422	T28	Resistant	2.5	2.0	25.0	3.0	10.0	5.0	>100	40.0	12.5	35.0	1.5
subsp. *bolletii* M232	T28	Resistant	2.5	2.0	40.0	3.5	15.0	8.0	>100	50.0	15.0	40.0	2.0
subsp. *bolletii* M506	C28	Sensitive	2.5	2.0	30.0	3.5	15.0	8.0	>100	70.0	18.0	35.0	0.4
subsp. *massiliense* M111	Deletion	Sensitive	4.0	3.5	35.0	4.0	15.0	10.0	>100	100.0	30.0	35.0	0.4

328 [a] Cultures were treated with increasing concentrations of β lactams without ('MIC') or with 4 µg/ml AVI ('MIC+') (27). Values present

329 the concentrations that achieved 90% inhibition of growth and are the means of three independent experiments. Note that AMX + AVI

330 achieved 80% inhibition of growth at ~10 µM (Figure S2).

331 [b] The clinically used parenteral comparators IPM and FOX were only tested alone as AVI does not affect activity of these β lactams

332 (Figure 1) (9).

333 [c] CLR, assay control. Note increased MIC values for CLR resistant strains.

334 [d] *erm41*, ribosome methylase gene conferring inducible CLR resistance. 'C28' and 'deletion'
335 sequevars are inactive *erm41* alleles and susceptible to CLR. The 'T28' sequevar is functional
336 and confers inducible resistance to CLR (3).
337 [e] *M. abscessus* Bamboo (37), K21 (38) and M strains (39) were reported previously.

Table 2. Checkerboard growth inhibition analysis of pairwise combinations of SUP, TBP, CXM, and AMX in the presence of 4 µg/mL AVI against *M. abscessus* ATCC19977.

β-lactams	**MIC [µM]**		**FICI** [c]	**Interpretation** [d]
	Alone [a]	Comb [b]		
SUP TBP	4.0 2.5	0.5 1.2	0.61	Additive
SUP CXM	4.0 5.0	0.8 2.0	0.60	Additive
SUP AMX	4.0 25.0	0.5 6.0	0.37	Synergy
TBP CXM	2.5 5.0	1.5 1.0	0.80	Additive
TBP AMX	2.5 25.0	0.5 6.0	0.44	Synergy
CXM AMX	5.0 25.0	0.8 3.0	0.28	Synergy

[a] MIC of single drugs, with 4 µg/mL AVI in the case of TBP, CXM and AMX.

[b] MIC of the combination (all in the presence of 4 µg/mL AVI as at least one partner drugs require AVI for activity).

[c] Fractional Inhibitory Concentration Index, calculated using the concentration at which at least 90% growth inhibition of the cultures was observed. FICI = [(concentration of drug A in combination / concentration of drug A alone) + (concentration of drug B in combination / concentration of drug B alone)].

[d] FICI, ≤ 0.5, synergistic; 0.5 to 1.0, additive; > 1.0 to < 2, indifferent; ≥ 2.0, antagonistic (40).

The experiment was repeated once yielding similar results.

357 **Table 3.** Checkerboard growth inhibition analysis of SUP+AMX, TBP+AMX and CXM+AMX in the presence of 4 µg/mL AVI

358 against *M. abscessus* complex strains.

***M. abscessus* strain**	**SUP+AMX**					**TBP+AMX**					**CXM+AMX**				
	MIC [µM] [a]				**FICI [b]**	**MIC [µM] [a]**				**FICI [b]**	**MIC [µM] [a]**				**FICI [b]**
	SUP Alone	AMX Alone	SUP Comb	AMX Comb		TBP Alone	AMX Alone	TBP Comb	AMX Comb		CXM Alone	AMX Alone	CXM Comb	AMX Comb	
Reference strains															
subsp. *abscessus* ATCC19977	2.5	25.0	0.5	7.0	0.48	4.0	25.0	0.4	7.0	0.38	6.3	25	0.5	4.0	0.24
subsp. *bolletii* CCUG50184T	2.5	50	0.7	10.0	0.48	4.0	50.0	1.0	4.0	0.33	8.0	50.0	1.5	6.3	0.31
subsp. *massiliense* CCUG48898T	4.0	100	1.0	25.0	0.50	8.0	100.0	1.0	10.0	0.22	12.5	100.0	1.5	25	0.37
Clinical isolates															
subsp. *abscessus* Bamboo	2.5	50.0	0.5	10.0	0.40	4.5	40.0	0.5	5.0	0.24	8.0	50.0	1.5	5.0	0.29
subsp. *abscessus* K21	5.0	100.0	1.0	25.0	0.45	5.0	100.0	1.5	12.5	0.43	12.5	100.0	1.5	6.3	0.18
subsp. *abscessus* M9	2.5	50.0	0.5	10.0	0.40	4.0	50.0	0.8	6.3	0.33	6.3	50.0	0.8	12.5	0.38
subsp. *abscessus* M199	2.5	100.0	0.5	25.0	0.45	4.5	80.0	0.5	10.0	0.24	8.0	100.0	1.5	10.0	0.29
subsp. *abscessus* M337	2.0	75.0	0.4	25.0	0.53	4.5	75.0	0.8	12.5	0.34	8.0	75.0	1.5	10.0	0.32
subsp. *abscessus* M404	2.0	50.0	0.4	12.5	0.45	4.5	50.0	0.8	6.3	0.30	8.0	50.0	1.0	5.0	0.23
subsp. *abscessus* M422	2.5	50.0	0.5	10.0	0.40	4.5	50.0	0.5	6.0	0.23	8.0	50.0	1.5	5.0	0.29
subsp. *bolletii* M232	2.5	50.0	0.8	12.5	0.57	4.5	50.0	1.0	6.3	0.35	8.0	50.0	2.0	6.3	0.38
subsp. *bolletii* M506	2.5	75.0	0.5	15.0	0.40	4.5	75.0	0.5	10.0	0.24	8.0	80.0	1.5	10.0	0.31
subsp. *massiliense* M111	2.5	100.0	0.8	25.0	0.57	4.5	75.0	0.8	12.5	0.34	8.0	100.0	1.5	8.0	0.27

359

360 [a] Alone and Comb as described in Table 2.

361 [b] FICI, ≤ 0.5, synergistic; 0.5 to 1.0, additive (40).

362 **FIGURES LEGENDS**

363 **Fig. 1.** Single point growth inhibition screen of β-lactams with and without 4 μg/mL AVI against
364 *M. abscessus* ATCC19977. A collection of the bioactive forms of 22 oral β-lactams was screened
365 at 12.5 μM. Percent growth inhibition is shown. Dashed line, 80% growth inhibition. CLR was
366 included as positive control, IPM and FOX as clinically used parenteral comparators. The
367 experiment was carried out twice yielding similar results. Compound sources, oral prodrug forms
368 (if applicable) and clinical status are described in Table S1.

369 **Fig. 2.** Dose response time-kill curves of SUP, TBP+AVI, CXM+AVI and AMX-AVI against
370 *M. abscessus* ATCC19977 and drug stability in culture medium and mouse plasma. (A) Time
371 concentration kill curves. Cultures of *M. abscessus* ATCC19977 were treated with MIC (Table
372 1) and multiples of MIC of SUP (alone), TBP, CXM, AMX (in combination with 4 ug/mL AVI)
373 for 5 days and viability of the cultures was monitored by CFU determination. CLR was included
374 as assay control. IPM and FOX were included as clinically used parenteral comparators. (B)
375 Stability of the β-lactams tested in (A) and AVI in 7H9 broth over a 5-day incubation period at
376 37ºC. Percent remaining was calculated relative to time 0 concentration (10 μM). Half-life was
377 estimated from the decay curves. (C) Mouse plasma stability of the four oral β-lactams and AVI
378 over 1-day incubation period. Experiments in (A) were performed twice independently,
379 generating similar data, and one representative set is shown. Experiments in (B) and (C) were
380 carried out twice independently and means and standard deviations are shown.

381 **Fig. 3.** Time-kill curves of SUP+AMX, TBP+AMX and CXM+AMX in the presence of 4
382 μg/mL AVI against *M. abscessus* ATCC19977. Red curves: Cultures of *M. abscessus*
383 ATCC19977 were treated with 1x MIC of SUP, TBP or CXM (Table 1) with or without 10, 5 or
384 2.5 μM AMX in the presence of 4 μg/mL AVI for 5 days. Note, 10 μM AMX suppresses growth

385 by 80% (Figure S2). Bacterial viability was monitored by CFU determination. Blue curves:
386 treatment of cultures with 10, 5, 2.5 μM AMX alone in the presence of 4 μg/mL AVI. LOD,
387 limit of detection (100 CFU/mL). The experiment was carried out twice independently,
388 generating similar results, and one representative set of plots is shown.

389

390


Clarithromycin (CLR)
+ AVI
- AVI
Penems
Carbapenems
Sulopenem (SUP)
Faropenem (FPM)
Tebipenem (TBP)
Imipenem (IPM)
Cephalosporins
Cephalexin (LEX)
Cefaclor (CEC)
Cefradine (CED)
Ceftibuten (CTB)
Cefprozil (CPR)
Cefpodoxime (CPD)
Cefixime (CFM)
Cefdinir (CDR)
Cefadroxil (CFR)
Cefuroxime (CXM)
Cefditoren (CDN)
Cefetamet (FET)
Cefoxitin (FOX)
Penicillins
Penicillin V (PcV)
Amdinocillin (AMD)
Flucloxacillin (FLX)
Dicloxacillin (DCX)
Cloxacillin (CLX)
Ampicillin (AMP)
Amoxicillin (AMX)
0
20
40
60
80
100
120
% Growth inhibition at 12.5 µM


A
SUP
TBP+AVI
CXM+AVI
AMX+AVI
IPM
FOX
CLR
log [CFU/ml]
Drug Free
AVI control
1x MIC
2x MIC
4x MIC
8x MIC
B
SUP
TBP
CXM
AMX
IPM
FOX
AVI
% Remaining
$t_{1/2}$~5d
$t_{1/2}$~1.4d
$t_{1/2}$~1.4d
$t_{1/2}$~4d
$t_{1/2}$~0.5d
$t_{1/2}$~2d
$t_{1/2}$>5d
Time (days)
C
SUP
TBP
CXM
AMX
AVI
% Remaining
$t_{1/2}$~17h
$t_{1/2}$>24h
$t_{1/2}$~20h
$t_{1/2}$~24h
$t_{1/2}$>24h
Time (h)


SUP + AMX
TBP + AMX
CXM + AMX
log [CFU/ml]
Time (h)
LOD
0
2
4
6
8
10
12
0 1 2 3 4 5
Drug Free
AMX 2.5 μM
AMX 5 μM
AMX 10 μM
1x MIC + AMX 0 μM
1x MIC + AMX 2.5 μM
1x MIC + AMX 5 μM
1x MIC + AMX 10 μM
Below LOD